Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$14.81

0.38 (2.63%)

07:36
06/19/17
06/19
07:36
06/19/17
07:36

CRISPR Therapeutics announces patent for CRISPR/Cas Genome editing in China

CRISPR Therapeutics announced that China's State Intellectual Property Office, or SIPO, has granted a patent broadly covering CRISPR's in-licensed gene editing technology. The claims are directed to CRISPR/Cas9 single-guide gene editing methods for modifying target DNA in both non-cellular and cellular settings, including in cells from vertebrate animals such as human or mammalian cells - as well as composition of matter and system claims for use in any setting, including claims for use in producing medicines for treating disease.

  • 22

    Jun

CRSP Crispr Therapeutics
$14.81

0.38 (2.63%)

11/15/16
SBSH
11/15/16
INITIATION
Target $19
SBSH
Neutral
CRISPR Therapeutics initiated with a Neutral at Citi
Citi analyst Yigal Nochomovitz started CRISPR Therapeutics with a Neutral rating and $19 price target. The risk/reward is balanced with the stock up 25% since the initial public offering, Nochomovitz tells investors in a research note. The analyst sees "no clear winner" in the gene editing patent debate.
02/15/17
JEFF
02/15/17
NO CHANGE
JEFF
Patent ruling best case for Editas Medicine, says Jefferies
Jefferies analyst Gena Wang views the United States Patent and Trademark Office's judgment of "no interference-in-fact" for the CRISPR/Cas9 interference motion phase as the "best case" for Editas Medicine (EDIT), Broad Institute's licensee. The analyst sees three choices for The University of California, which has CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) as licensees: Appeal, seek second interference, or discuss a settlement. Wang sees cross-licensing as the likely eventual path taken by both parties. CRISPR and Intellia could license from Editas the use of CRISPR in eukaryotic cells, while Editas could license from the two companies the use of single guide and tracrRNA, the analyst tells investors in a research note. She believes a royalty could be in the mid-single-digit range. Shares of Editas are up 33% to $24.99 in afternoon while CRISPR is down 13% to $15.05 and Intellia is down 11% to $12.26.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.

TODAY'S FREE FLY STORIES

SYRS

Syros Pharmaceuticals

$20.17

-0.03 (-0.15%)

08:06
08/21/17
08/21
08:06
08/21/17
08:06
Hot Stocks
Syros Pharmaceuticals receives orphan drug designation for SY-1425 »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$8.42

0.44 (5.51%)

08:05
08/21/17
08/21
08:05
08/21/17
08:05
Hot Stocks
Immunomedics reports 'encouraging' Phase 2 results of IMMU-130 »

Immunomedics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

IRWD

Ironwood

08:04
08/21/17
08/21
08:04
08/21/17
08:04
Hot Stocks
Ironwood receives FDA approval of DUZALLO »

Ironwood Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

HLF

Herbalife

$61.95

-0.26 (-0.42%)

08:04
08/21/17
08/21
08:04
08/21/17
08:04
Hot Stocks
Breaking Hot Stocks news story on Herbalife »

Herbalife announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$80.65

-0.25 (-0.31%)

08:04
08/21/17
08/21
08:04
08/21/17
08:04
Hot Stocks
Verisk Analytics to acquire Sequel from Hg Capital for GBP250M »

Verisk Analytics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLF

Herbalife

$61.95

-0.26 (-0.42%)

08:03
08/21/17
08/21
08:03
08/21/17
08:03
Hot Stocks
Breaking Hot Stocks news story on Herbalife »

Herbalife says was in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRME

Cardiome

$3.87

-0.02 (-0.51%)

08:03
08/21/17
08/21
08:03
08/21/17
08:03
Hot Stocks
Cardiome provides U.S. regulatory update on BRINAVESS »

Cardiome announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LH

LabCorp

$153.91

-0.65 (-0.42%)

08:03
08/21/17
08/21
08:03
08/21/17
08:03
Hot Stocks
LabCorp, OmniSeq sign distribution agreement, Series B funding commitment »

OmniSeq said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLNG

Golar LNG

$20.38

-0.23 (-1.12%)

08:02
08/21/17
08/21
08:02
08/21/17
08:02
Hot Stocks
Golar LNG says Fortuna FLNG offtake awarded to Gunvor »

The Ministry of Mines and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSC

TriState Capital

$21.15

0.1 (0.48%)

08:02
08/21/17
08/21
08:02
08/21/17
08:02
Hot Stocks
TriState Capital names David Demas CFO »

TriState Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

ESEA

Euroseas

08:01
08/21/17
08/21
08:01
08/21/17
08:01
Initiation
Euroseas initiated  »

Euroseas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$30.37

-0.67 (-2.16%)

08:01
08/21/17
08/21
08:01
08/21/17
08:01
Hot Stocks
Cisco announces intent to acquire Springpath for $320M in cash »

Cisco announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

EGLE

Eagle Bulk Shipping

$4.42

-0.03 (-0.67%)

07:59
08/21/17
08/21
07:59
08/21/17
07:59
Initiation
Eagle Bulk Shipping initiated  »

Eagle Bulk Shipping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.38

-13.32 (-27.92%)

, DKS

Dick's Sporting

$26.99

-0.75 (-2.70%)

07:59
08/21/17
08/21
07:59
08/21/17
07:59
Recommendations
Foot Locker, Dick's Sporting analyst commentary  »

Foot Locker weakness…

FL

Foot Locker

$34.38

-13.32 (-27.92%)

DKS

Dick's Sporting

$26.99

-0.75 (-2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 23

    Aug

VLO

Valero

$64.75

0.2 (0.31%)

07:56
08/21/17
08/21
07:56
08/21/17
07:56
Periodicals
Valero campaigns against U.S. biofuels regulations, Reuters says »

Oil refiner Valero Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NH

NantHealth

$3.00

-0.07 (-2.28%)

07:56
08/21/17
08/21
07:56
08/21/17
07:56
Recommendations
NantHealth analyst commentary  »

NantHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRKL

Brookline Bancorp

$13.78

0.025 (0.18%)

07:54
08/21/17
08/21
07:54
08/21/17
07:54
Upgrade
Brookline Bancorp rating change  »

Brookline Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

lululemon

$58.13

-0.83 (-1.41%)

07:53
08/21/17
08/21
07:53
08/21/17
07:53
Upgrade
lululemon rating change  »

lululemon upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Aug

  • 03

    Oct

  • 04

    Oct

ADNT

Adient

$65.97

0.42 (0.64%)

07:53
08/21/17
08/21
07:53
08/21/17
07:53
Conference/Events
Adient to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

INFY

Infosys

$14.79

-1.14 (-7.16%)

07:51
08/21/17
08/21
07:51
08/21/17
07:51
Downgrade
Infosys rating change  »

Infosys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 06

    Sep

NSU

Nevsun Resources

$2.09

0.02 (0.97%)

07:51
08/21/17
08/21
07:51
08/21/17
07:51
Hot Stocks
Nevsun Resources names Ryan MacWilliam as CFO, effective August 28 »

Nevsun Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:50
08/21/17
08/21
07:50
08/21/17
07:50
General news
Treasury Market Outlook: bond yields are modestly lower »

Treasury Market Outlook:…

TSEM

Tower Semiconductor

$25.02

-0.04 (-0.16%)

07:47
08/21/17
08/21
07:47
08/21/17
07:47
Hot Stocks
ToweJazz, Tacoma announce partnership for new 8-inch fab facility in China »

TowerJazz and Tacoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

QCOM

Qualcomm

$51.92

-0.35 (-0.67%)

, TSM

TSMC

$35.86

0.07 (0.20%)

07:46
08/21/17
08/21
07:46
08/21/17
07:46
Periodicals
Qualcomm, TSMC extend partnership to FinFet, DigiTimes says »

Qualcomm (QCOM) is…

QCOM

Qualcomm

$51.92

-0.35 (-0.67%)

TSM

TSMC

$35.86

0.07 (0.20%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

DOC

Physicians Realty Trust

$17.94

-0.24 (-1.32%)

07:44
08/21/17
08/21
07:44
08/21/17
07:44
Upgrade
Physicians Realty Trust rating change  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.